Repeat: Professor Paul Workman, of the Institute of Cancer Research, said the drug was a victim of its own success as its novel action meant it did not fit easily into the current system for assessing treatment.
Professor Paul Workman, of the Institute of Cancer Research, said the drug was a victim of its own success as its novel action meant it did not fit easily into the current system for assessing treatment.